Erasca (ERAS) Shares Outstanding (2020 - 2026)
Erasca's (ERAS) quarterly Shares Outstanding (Entity) came in at $310.8 million in Q1 2026, up 9.72% YoY from $283.3 million in Q1 2025, and up 9.38% on a QoQ basis from $284.2 million in Q4 2025.
Erasca (ERAS) Shares Outstanding (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Shares Outstanding (Entity) data on file, last reported at $310.8 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 9.72% year-over-year to $310.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $310.8 million (up 9.72% YoY) and the FY2025 annual result came in at $284.2 million, up 21.53% from the prior year.
- Shares Outstanding (Entity) advanced to $310.8 million in Q1 2026, from $284.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $310.8 million in Q1 2026 to a low of $121.7 million in Q1 2022.
- A 5-year average of $201.4 million and a median of $151.5 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 365.89% — and 2025, when it advanced 0.36%.
- Tracing ERAS's Shares Outstanding (Entity) over 5 years: stood at $122.0 million in 2022, then gained by 24.12% to $151.5 million in 2023, then jumped by 54.37% to $233.8 million in 2024, then advanced by 21.53% to $284.2 million in 2025, then gained by 9.38% to $310.8 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $310.8 million (Q1 2026), $284.2 million (Q4 2025), and $283.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 311.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 311.34 Mn |
| Mar 31, 2026 | 304.32 Mn |
| Dec 31, 2025 | 283.53 Mn |
| Sep 30, 2025 | 283.68 Mn |
| Jun 30, 2025 | 283.36 Mn |
| Mar 31, 2025 | 283.26 Mn |
| Dec 31, 2024 | 233.82 Mn |
| Sep 30, 2024 | 282.38 Mn |
| Jun 30, 2024 | 217.81 Mn |
| Mar 31, 2024 | 151.16 Mn |
| Dec 31, 2023 | 150.18 Mn |
| Sep 30, 2023 | 150.45 Mn |
| Jun 30, 2023 | 150.04 Mn |
| Mar 31, 2023 | 149.50 Mn |
| Dec 31, 2022 | 122.02 Mn |
| Sep 30, 2022 | 120.80 Mn |
| Jun 30, 2022 | 120.19 Mn |
| Mar 31, 2022 | 119.49 Mn |
| Dec 31, 2021 | 66.29 Mn |
| Sep 30, 2021 | 99.13 Mn |